Blood test to predict response to chemo-immunotherapy in triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies a simple blood test that may predict how well your body responds to chemotherapy plus immunotherapy before surgery for triple-negative breast cancer. The goal is to use these clues to personalize your treatment in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- You must have stage II or III triple-negative breast cancer (meaning the tumor doesn't have the three common receptors).
- You will be receiving chemotherapy combined with immunotherapy before surgery, as part of your standard care.
- You must be scheduled to have a small clip placed in the breast to mark the tumor area.
- You cannot have cancer that has spread to other organs, and you must not have had surgery yet for this breast cancer.
- You must not have certain infections (HIV, hepatitis C, or active hepatitis B) or other uncontrolled medical conditions that affect blood clotting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the bacteria found in the tumor to see if they affect how well chemotherapy or immunotherapy works in treating triple-negative breast cancer. The goal is to find ways to predict treatment response and improve care.
This study helps doctors predict which patients will respond best to immunochemotherapy (a combination of immune-boosting and chemotherapy drugs) for early-stage triple-negative breast cancer. By understanding your tumor better before treatment, doctors may be able to personalize your care plan.
This study is testing a way to use a simple blood test during chemotherapy to see how well the treatment is working in certain breast cancers. The goal is to make sure you get the best treatment for your tumor type.
This trial is testing whether a blood test can track how well chemotherapy is working in people with early-stage triple-negative breast cancer. You would provide blood samples before and during treatment, and the results may help your doctor understand your response better.
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
This trial uses special imaging before and after treatment to see if it can predict how well triple-negative breast cancer responds to chemotherapy plus immunotherapy given before surgery. Participation could help doctors tailor future treatments.
Hear when a new Triple-negative Breast Cancer (TNBC), Stage II-III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.